https://orcid.org/0000-0002-5101-7289
Figures & data
Table 1 Patient Demographics and Clinical Characteristics of Patients Treated with Palbociclib During the Whole Study Period
Table 2 Median Follow-Up Times (95% CI) for the Whole Patient Population, the Palbociclib Plus AI, and Palbociclib Plus Fulvestrant Cohorts During the Whole Study Period (May 1, 2017–June 30, 2019), and Separately for the NPBR (May 1, 2017–October 1, 2018) and Regular Reimbursement Periods (October 15, 2018–June 30, 2019)
Table 3 Treatment Patterns of Patients Receiving Palbociclib Therapy During the Whole Study Period
Table 4 Most Common Comorbidities of Patients Treated with Palbociclib
Table 5 Concomitant Medications with a Potential for Drug–Drug Interactions for CDK4/6 Inhibitors Among Patients Treated with Palbociclib
Table 6 Polypharmacy in Patients Treated with Palbociclib – 45 Days Prior to and/or During Palbociclib Initiation, ACT5 Level
Table 7 Palliative Oncology Care in Patients Treated with Palbociclib